Bristol Myers Squibb (BMS) is strategically positioning itself for sustained growth through the 2030s, with upcoming pivotal Phase III readouts…
Read More

Bristol Myers Squibb (BMS) is strategically positioning itself for sustained growth through the 2030s, with upcoming pivotal Phase III readouts…
Read More
The U.S. Food and Drug Administration (FDA) has granted approval for a higher-dose formulation of Novo Nordisk’s blockbuster weight-loss medication,…
Read More